Disturbed dental development of permanent teeth in children with solid tumors and lymphomas

Çubukçu, Çiğdem Elbek; Sevinir, Betül; Ercan, İlker

doi:10.1002/pbc.22902

Cited by 42 publications

(63 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(2012) compared the DeI in children under chemotherapy (27 children) and in those under chemo- and radiation therapy (10 children) to DeI in controls. According to their study, DeI> 1 also occurred in 100% of patients and in 12.9% of controls [57]. In the present study, congenital tooth abnormalities, visible on pantomographs, occurred more often in patients after chemotherapy than in controls.…”

Section: Discussionsupporting

confidence: 59%

See 1 more Smart Citation

Antineoplastic chemotherapy and congenital tooth abnormalities in children and adolescents

Krasuska-Sławińska

Brożyna

Dembowska‐Bagińska

et al. 2016

View full text Add to dashboard Cite

Aim of the studyChemotherapeutic treatment in children and adolescents carries a risk of congenital tooth disorders and dentinoma. Study objective is to assess the correlation between tooth abnormalities, early complications of multidrug chemotherapy, and chemotherapeutics used in different antineoplastic therapies in children and adolescents.Material and methodsEnamel defects (developmental defects of enamel index – DDE index) and defects in tooth number, size, and structure were assessed clinically and radiologically in 60 patients who underwent chemotherapy on average 4.9 ±3.4 years earlier (PCH), and 60 generally healthy subjects (control group – CG), aged 6–18 years. Höltta’s defect index (DeI) was calculated. Medical files provided information on neoplasm type, age at treatment start and chemotherapy duration, chemotherapeutic type and dose, vomiting, and mucositis (CTCAE v4.0). Statistical significance of differences between groups was assessed with the Mann-Whitney U test and the correlation between dental defects and chemotherapy with Spearman’s rank correlation coefficient (significance p ≤ 0.05).ResultsEnamel defects, tooth agenesis, microdontia, root resorption, taurodontism, and dentinoma occurred statistically significantly more often in the PCH group. A correlation was established between vincristine use and dose and all types of dental defects; cyclophosphamide, doxorubicin, and isophosphamide and hypodontia; microdontia, root resorption, and enamel defects; etoposide and cisplatin and microdontia, root resorption, and enamel defects; methotrexate root resorption and enamel defects; carboplatin and dentinoma and enamel defects. Mucositis and vomiting promoted root resorption, microdontia, and enamel defects.ConclusionsDental defects are related to both the use of respective chemotherapeutics, especially vincristine, cyclophosphamide, doxorubicin, and isophosphamide, and to early complications in multidrug chemotherapy – mucositis and vomiting. Vincristine and carboplatin use may promote dentinoma.

show abstract

Section: Discussionsupporting

confidence: 59%

“…Since chemotherapy protocols include a couple of chemotherapeutics, there is no information on the impact of the respective drugs on odontogenesis. The available research presents all the types and prevalence of dental congenital abnormalities [14, 21–24, 57]. Maciel et al .…”

Section: Discussionmentioning

confidence: 99%

Antineoplastic chemotherapy and congenital tooth abnormalities in children and adolescents

Krasuska-Sławińska

Brożyna

Dembowska‐Bagińska

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These include hypodontia, microdontia, enamel hypoplasia, and root malformation. 77 Risk factors include younger age at treatment (e.g., age <5 years), higher doses of alkylating agents (especially cyclophosphamide), and radiation exposure. 76 Radiation doses as low as 10 Gy have resulted in permanent damage to tooth development.…”

Section: Dentalmentioning

confidence: 99%

Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report

Chow

Anderson

Baker

et al. 2016

Biology of Blood and Marrow Transplantation

166

152

View full text Add to dashboard Cite

Hematopoietic cell transplantation (HCT) is an important curative treatment for children with high-risk hematologic malignancies and solid tumors, and increasingly, non-malignant diseases. Given improvements in care, there is a growing number of long-term survivors of pediatric HCT. Compared with non-transplanted childhood cancer survivors, HCT survivors have been shown to have a substantially increased burden of serious chronic conditions and impairments involving virtually every organ system and overall quality of life. This likely reflects the joint contributions of pre-transplant treatment exposures and organ dysfunction, the transplant conditioning regimen, and any post-transplant graft versus host disease (GVHD). In response, the Children’s Oncology Group (COG) has created Long-Term Follow-Up Guidelines (www.survivorshipguidelines.org) for survivors of childhood, adolescent, and young adult cancer, including those treated with HCT. Guidelines taskforces, consisting of HCT specialists, other pediatric oncologists, radiation oncologists, organ-specific subspecialists, nurses, social workers, other healthcare professionals, and patient advocates have systematically reviewed the literature with regards to late effects after childhood cancer and HCT since 2002, with the most recent review completed in 2013. For the most recent review cycle, over 800 articles from the medical literature relevant to childhood cancer and HCT survivorship were reviewed, including 586 original research articles. Provided here-in is an organ system-based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence. These recommendations cover both autologous and allogeneic HCT survivors, those transplanted for non-malignant diseases, and those with a history of chronic GVHD.

show abstract

“…Formation and eruption of permanent dentition occurs from approximately 6 to 12 years [11]. The temporal disruption or modifications of this network by cancer therapy administered during stages of tooth development can cause dental anomalies [12, 13] (Figs. 1, 2, and 3).…”

Section: Resultsmentioning

confidence: 99%

“…Structural anomalies of teeth, including hypodontia, microdontia, enamel hypoplasia, and root malformation, are increasingly recognized after childhood cancer treatment [12, 13]. The prevalence of hypodontia, which may alter craniofacial development and lead to malocclusion [14, 15], has ranged from 8.5 to 50 % depending on age at diagnosis, treatment modality, and study ascertainment methods [16–18].…”

Section: Resultsmentioning

confidence: 99%

Oral and dental late effects in survivors of childhood cancer: a Children’s Oncology Group report

Effinger¹,

Migliorati²,

Hudson³

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

Purpose Multi-modality therapy has resulted in improved survival for childhood malignancies. The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers provide practitioners with exposure- and risk-based recommendations for the surveillance and management of asymptomatic survivors who are at least 2 years from completion of therapy. This review outlines the pathophysiology and risks for oral and dental late effects in pediatric cancer survivors and the rationale for oral and dental screening recommended by the Children’s Oncology Group. Methods An English literature search for oral and dental complications of childhood cancer treatment was undertaken via MEDLINE and encompassed January 1975 to January 2013. Proposed guideline content based on the literature review was approved by a multi-disciplinary panel of survivorship experts and scored according to a modified version of the National Comprehensive Cancer Network “Categories of Consensus” system. Results The Children’s Oncology Group oral-dental pan el selected 85 relevant citations. Childhood cancer therapy may impact tooth development, salivary function, craniofacial development, and temporomandibular joint function placing some childhood cancer survivors at an increased risk for poor oral and dental health. Addition ally, head and neck radiation and hematopoietic stem cell transplantation increase the risk of subsequent ma lignant neoplasms in the oral cavity. Survivors require routine dental care to evaluate for potential side effects and initiate early treatment. Conclusions Certain childhood cancer survivors are at an increased risk for poor oral and dental health. Early identification of oral and dental morbidity and early interventions can optimize health and quality of life.

show abstract

Disturbed dental development of permanent teeth in children with solid tumors and lymphomas

Cited by 42 publications

References 16 publications

Antineoplastic chemotherapy and congenital tooth abnormalities in children and adolescents

Antineoplastic chemotherapy and congenital tooth abnormalities in children and adolescents

Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report

Oral and dental late effects in survivors of childhood cancer: a Children’s Oncology Group report

Contact Info

Product

Resources

About